These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7593438)

  • 1. Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion.
    Lanzi R; Andreotti AC; Caumo A; Manzoni MF; Losa M; Malighetti ME; Pontiroli AE
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3279-83. PubMed ID: 7593438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men.
    Shah N; Aloi J; Evans WS; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2862-9. PubMed ID: 10443692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.
    Weeke J; Christensen SE; Orskov H; Kaal A; Pedersen MM; Illum P; Harris AG
    J Clin Endocrinol Metab; 1992 Jul; 75(1):163-9. PubMed ID: 1619006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin decreases circulating growth hormone levels in acromegaly.
    Giustina A; Bodini C; Doga M; Schettino M; Pizzocolo G; Giustina G
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1296-300. PubMed ID: 1375598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
    Gelato MC; Oldfield E; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M; Schopohl J; König A; Müller OA; von Werder K
    J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
    Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone-releasing hormone infusion in patients with active acromegaly.
    Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The control on growth hormone release by free fatty acids is maintained in acromegaly.
    Lanzi R; Losa M; Mignogna G; Caumo A; Pontiroli AE
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of octreotide treatment on pulsatile growth hormone release in acromegaly.
    Roelfsema F; de Boer H; Frölich M
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):297-306. PubMed ID: 2225485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly.
    Nicholls J; Wynick D; Domin J; Sandler LM; Bloom SR
    Clin Endocrinol (Oxf); 1990 May; 32(5):545-50. PubMed ID: 2364560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
    Lamberts SW; Oosterom R; Neufeld M; del Pozo E
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
    Minniti G; Jaffrain-Rea ML; Baldelli R; Ferretti E; Caracciolo B; Bultrini A; Gulino A; Tamburrano G
    Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.